NCT03471650View on ClinicalTrials.gov

Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer

PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

150

Participants

Timeline

Start Date

March 29, 2018

Primary Completion Date

March 7, 2027

Study Completion Date

March 7, 2027

Conditions
Prostate Cancer
Interventions
DRUG

18F-DCFPyL Injection

A bolus of \~9 mCi (333 MBq) of 18F-DCFPyL will be injected by slow IV push.

Trial Locations (1)

21287

SKCCC, Baltimore

All Listed Sponsors
collaborator

Progenics Pharmaceuticals, Inc.

INDUSTRY

lead

Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

OTHER

NCT03471650 - Study of PSMA-targeted 18F-DCFPyL PET/CT for the Detection of Clinically Significant Prostate Cancer | Biotech Hunter | Biotech Hunter